Collegium Pharmaceutical (NASDAQ:COLL) had its target price hoisted by Jefferies Group to $27.00 in a report released on Tuesday, The Fly reports. The firm currently has a buy rating on the specialty pharmaceutical company’s stock. Jefferies Group also issued estimates for Collegium Pharmaceutical’s FY2021 earnings at $1.36 EPS.

Other analysts have also issued research reports about the company. HC Wainwright began coverage on Collegium Pharmaceutical in a research report on Monday, September 11th. They issued a buy rating and a $21.00 target price on the stock. Zacks Investment Research raised Collegium Pharmaceutical from a sell rating to a hold rating in a research report on Monday, August 14th. Piper Jaffray Companies set a $19.00 target price on Collegium Pharmaceutical and gave the company a buy rating in a research report on Wednesday, November 29th. Finally, Needham & Company LLC reissued a buy rating and issued a $25.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating and six have issued a buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $23.50.

Collegium Pharmaceutical (NASDAQ COLL) traded down $0.64 on Tuesday, reaching $17.70. The company had a trading volume of 1,342,032 shares, compared to its average volume of 1,208,443. Collegium Pharmaceutical has a 12-month low of $7.37 and a 12-month high of $20.92.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.28. The firm had revenue of $11.95 million for the quarter, compared to analysts’ expectations of $5.31 million. Collegium Pharmaceutical had a negative return on equity of 77.11% and a negative net margin of 447.83%. The firm’s quarterly revenue was up 2814.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.13) earnings per share. equities analysts anticipate that Collegium Pharmaceutical will post -2.56 EPS for the current fiscal year.

In other news, CEO Michael Thomas Heffernan sold 50,000 shares of the company’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $15.53, for a total transaction of $776,500.00. Following the sale, the chief executive officer now owns 558,987 shares of the company’s stock, valued at $8,681,068.11. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Alison B. Fleming sold 4,601 shares of the company’s stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $17.25, for a total value of $79,367.25. Following the sale, the insider now directly owns 28,513 shares in the company, valued at approximately $491,849.25. The disclosure for this sale can be found here. Insiders have sold 58,630 shares of company stock worth $924,360 in the last ninety days. Corporate insiders own 25.76% of the company’s stock.

Several institutional investors have recently bought and sold shares of COLL. Sectoral Asset Management Inc increased its position in shares of Collegium Pharmaceutical by 41.4% during the second quarter. Sectoral Asset Management Inc now owns 1,808,750 shares of the specialty pharmaceutical company’s stock worth $22,627,000 after acquiring an additional 529,503 shares during the period. Citadel Advisors LLC increased its position in shares of Collegium Pharmaceutical by 773.8% during the third quarter. Citadel Advisors LLC now owns 544,033 shares of the specialty pharmaceutical company’s stock worth $5,707,000 after acquiring an additional 481,771 shares during the period. Macquarie Group Ltd. increased its position in shares of Collegium Pharmaceutical by 37.1% during the second quarter. Macquarie Group Ltd. now owns 1,118,691 shares of the specialty pharmaceutical company’s stock worth $13,995,000 after acquiring an additional 302,892 shares during the period. Prudential Financial Inc. increased its position in shares of Collegium Pharmaceutical by 62.8% during the third quarter. Prudential Financial Inc. now owns 557,050 shares of the specialty pharmaceutical company’s stock worth $5,843,000 after acquiring an additional 214,860 shares during the period. Finally, Pura Vida Investments LLC purchased a new stake in shares of Collegium Pharmaceutical during the third quarter worth $1,229,000. 79.98% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece was originally published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.dailypolitical.com/2017/12/09/collegium-pharmaceutical-coll-price-target-raised-to-27-00-at-jefferies-group.html.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

The Fly

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.